Hostname: page-component-77f85d65b8-8v9h9 Total loading time: 0 Render date: 2026-03-27T09:36:56.377Z Has data issue: false hasContentIssue false

Analysis of influenza data generated by four epidemiological surveillance laboratories in Mexico, 2010–2016

Published online by Cambridge University Press:  02 May 2019

L. Fernandes-Matano
Affiliation:
Laboratorio Central de Epidemiología, División de Laboratorios de Vigilancia e Investigación Epidemiológica, IMSS, Ciudad de México, Mexico Escuela Nacional de Ciencias Biológicas, IPN, Ciudad de México, Mexico
I. E. Monroy-Muñoz
Affiliation:
Laboratorio de Genómica, Departamento de Genética y Genómica Humana, Instituto Nacional de Perinatología ‘Isidro Espinosa de los Reyes’, Ciudad de México, Mexico
M. Bermúdez de León
Affiliation:
Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste IMSS, Monterrey, N.L., Mexico Departamento de Ciencias Básicas, Vicerrectoria de Ciencias de la Salud, Universidad de Monterrey, Av. Ignacio Morones Prieto 4500 Pte., 66238, San Pedro Garza García, N.L., Mexico
Y. A. Leal-Herrera
Affiliation:
Unidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Centro Médico Nacional ‘Ignacio García Téllez’ IMSS, Mérida, Yucatán, Mexico Laboratorio de Apoyo a la Vigilancia Epidemiológica (LAVE), Unidad Médica de Alta Especialidad, CMN ‘Ignacio García Téllez’ IMSS, Mérida, Yucatán, Mexico
I. D. Palomec-Nava
Affiliation:
Laboratorio Central de Epidemiología, División de Laboratorios de Vigilancia e Investigación Epidemiológica, IMSS, Ciudad de México, Mexico
J. A. Ruíz-Pacheco
Affiliation:
Cátedra CONACyT, División de Investigación Quirúrgica, Centro de Investigación Biomédica de Occidente IMSS, Guadalajara, Jal., Mexico
B. L. Escobedo-Guajardo
Affiliation:
Laboratorio de Diagnóstico Molecular Departamento de Biología Molecular, Centro de Investigación Biomédica del Noreste IMSS, Monterrey, N.L., Mexico
C. Marín-Budip
Affiliation:
Unidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Centro Médico Nacional ‘Ignacio García Téllez’ IMSS, Mérida, Yucatán, Mexico
C. E. Santacruz-Tinoco
Affiliation:
Laboratorio Central de Epidemiología, División de Laboratorios de Vigilancia e Investigación Epidemiológica, IMSS, Ciudad de México, Mexico
J. González-Ibarra
Affiliation:
División de Laboratorios de Vigilancia e Investigación Epidemiológica, IMSS, Ciudad de México, Mexico
C. R. González-Bonilla
Affiliation:
División de Laboratorios de Vigilancia e Investigación Epidemiológica, IMSS, Ciudad de México, Mexico
J. E. Muñoz-Medina*
Affiliation:
Laboratorio Central de Epidemiología, División de Laboratorios de Vigilancia e Investigación Epidemiológica, IMSS, Ciudad de México, Mexico
*
Author for correspondence: J. E. Muñoz-Medina, E-mail: eban10@hotmail.com
Rights & Permissions [Opens in a new window]

Abstract

The disease caused by the influenza virus is a global public health problem due to its high rates of morbidity and mortality. Thus, analysis of the information generated by epidemiological surveillance systems has vital importance for health decision making. A retrospective analysis was performed using data generated by the four molecular diagnostic laboratories of the Mexican Social Security Institute between 2010 and 2016. Demographics, influenza positivity, seasonality, treatment choices and vaccination status analyses were performed for the vaccine according to its composition for each season. In all cases, both the different influenza subtypes and different age groups were considered separately. The circulation of A/H1N1pdm09 (48.7%), influenza A/H3N2 (21.1%), influenza B (12.6%), influenza A not subtyped (11%) and influenza A/H1N1 (6.6%) exhibited well-defined annual seasonality between November and March, and there were significant increases in the number of cases every 2 years. An inadequate use of oseltamivir was determined in 38% of cases, and the vaccination status in general varied between 12.1 and 18.5% depending on the season. Our results provide current information about influenza in Mexico and demonstrate the need to update both operational case definitions and medical practice guidelines to reduce the inappropriate use of antibiotics and antivirals.

Information

Type
Original Paper
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © The Author(s) 2019
Figure 0

Table 1. Demographic data for the samples included in the study

Figure 1

Fig. 1. Influenza positivity from 2010 to 2016. The figure shows the positivity observed and the influenza subtypes identified during the study period.

Figure 2

Fig. 2. Seasonality of influenza and negative cases from 2010 to 2016. The figure shows the monthly circulation of influenza, the negative cases and each subtype identified during the study period (2010–2016). (a) Total, positive and negative cases of influenza and (b) influenza subtypes.

Figure 3

Fig. 3. Analysis of the proportion of different subtypes in each age group from 2010 to 2016. The figure shows the proportion of influenza cases in general and by subtype in each age group throughout the study period. (a) Total; (b) 2010; (c) 2011; (d) 2012; (e) 2013; (f) 2014; (g) 2015 and (h) 2016.

Figure 4

Table 2. Symptomatology, mortality rate and hospitalisation by influenza strain

Figure 5

Fig. 4. Deaths in general and by influenza subtype from 2010 to 2016. The figure shows monthly deaths in general and by subtype of influenza from 2010 to 2016. (a) In the total sample, in the positive ones and in the negative ones for influenza and (b) in each subtype.

Figure 6

Fig. 5. Percentage of positive cases with vaccination history in each season. The figure shows the percentages of positive cases with a history of vaccination for each subtype of influenza and for the positive samples in general.

Figure 7

Table 3. Relationship between the prescribed treatment and the laboratory result